Methods and compositions relating to glp1r variants
AssigneeTwist Bioscience Corporation
InventorsAaron SATO, Pankaj GARG, Qiang LIU, Fumiko AXELROD
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for immunoglobulins that bind to GLP1R. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.
Claims24
An antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs:
- 441-619;
- (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs:
- 620-798;
- (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs:
- 799-977;
- (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs:
- 978-1156;
- (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs:
- 1157-1335;
- and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs:
- 1336-1514.
(canceled)
(canceled)
A method of treating a metabolic disease or disorder comprising administering an antibody or antibody fragment that binds GLP1R comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs:
- 441-619;
- (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs:
- 620-798;
- (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs:
- 799-977;
- (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs:
- 978-1156;
- (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs:
- 1157-1335;
- and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs:
- 1336-1514.
-26. (canceled)
-36. (canceled)
Dependencies are inferred from the claim text.